(Reuters) – AstraZeneca said on Thursday it has begun a late-stage trial to test if its diabetes drug Farxiga can reduce the risk of serious complications and organ failure in COVID-19 patients who have existing heart and kidney problems.
The British drugmaker said the goal of the clinical study was to assess if Farxiga could cut the risk of the disease worsening and death in such patients.
(Reporting by Pushkala Aripaka in Bengaluru; Editing by Saumyadeb Chakrabarty)
